{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"38","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.\n\nlapatinib ditosylate: Given orally\n\ncapecitabine: Given orally","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"percentage"}